Anne M.L. Jansen

665 total citations
23 papers, 387 citations indexed

About

Anne M.L. Jansen is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Anne M.L. Jansen has authored 23 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Anne M.L. Jansen's work include Cancer Genomics and Diagnostics (9 papers), Genetic factors in colorectal cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Anne M.L. Jansen is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Genetic factors in colorectal cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Anne M.L. Jansen collaborates with scholars based in Netherlands, Australia and Denmark. Anne M.L. Jansen's co-authors include Johannes L. Bos, Jacques H. van Boom, A.J. van der Eb, G.H. Veeneman, Juul Wijnen, Carli M.J. Tops, Peter Devilee, Hans Morreau, Frederik J. Hes and Tom van Wezel and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Anne M.L. Jansen

17 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne M.L. Jansen Netherlands	7	193	153	138	130	56	23	387
Neal Fischbach United States	9	200 1.0×	230 1.5×	86 0.6×	88 0.7×	54 1.0×	21	499
Stefan C. Dentro United Kingdom	10	272 1.4×	165 1.1×	60 0.4×	240 1.8×	72 1.3×	13	498
Jessica C. Price United States	7	368 1.9×	119 0.8×	84 0.6×	145 1.1×	52 0.9×	8	551
Lee Trani United States	6	118 0.6×	116 0.8×	90 0.7×	64 0.5×	56 1.0×	6	276
Javíer Santos Spain	12	209 1.1×	121 0.8×	67 0.5×	86 0.7×	41 0.7×	28	366
Amjad Alkodsi Finland	12	222 1.2×	206 1.3×	137 1.0×	222 1.7×	59 1.1×	18	494
Roser Calvo United States	9	243 1.3×	109 0.7×	89 0.6×	75 0.6×	39 0.7×	17	404
Viktor Ljungström Sweden	11	139 0.7×	70 0.5×	110 0.8×	78 0.6×	29 0.5×	23	323
Tina Bedenham United Kingdom	3	373 1.9×	232 1.5×	166 1.2×	141 1.1×	130 2.3×	3	555
Seeta R. Chaganti United States	10	210 1.1×	188 1.2×	245 1.8×	106 0.8×	75 1.3×	14	521

Countries citing papers authored by Anne M.L. Jansen

Since Specialization

Citations

This map shows the geographic impact of Anne M.L. Jansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne M.L. Jansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne M.L. Jansen more than expected).

Fields of papers citing papers by Anne M.L. Jansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne M.L. Jansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne M.L. Jansen. The network helps show where Anne M.L. Jansen may publish in the future.

Co-authorship network of co-authors of Anne M.L. Jansen

This figure shows the co-authorship network connecting the top 25 collaborators of Anne M.L. Jansen. A scholar is included among the top collaborators of Anne M.L. Jansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne M.L. Jansen. Anne M.L. Jansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Froyen, Guy, Pieter‐Jan Volders, Joni Van der Meulen, et al.. (2025). Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics. Molecular Oncology. 19(6). 1797–1810.

Zeverijn, Laurien J., Joris van de Haar, Paul Roepman, et al.. (2025). The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP). ESMO Open. 10(1). 104112–104112.

Breimer, Gerben E., Nard G. Janssen, Anne M.L. Jansen, & Pieter J. Slootweg. (2025). Cemento-osseous dysplasia with a NOTCH4 mutation: a case report. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin.

Kester, Lennart, et al.. (2025). A Stranger in the Slide: A Rare Collision of a Spitz Melanocytoma With a Novel MYH9::LTK Fusion and a Common BRAF Mutated Nevus Mimicking a Melanoma With a Preexistent Nevus. American Journal of Dermatopathology. 47(8). 621–624.

Zeverijn, Laurien J., Birgit S. Geurts, Gijs F. de Wit, et al.. (2024). Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol. Clinical Cancer Research. 30(23). 5323–5332. 1 indexed citations

Mehra, Niven, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2024). Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.. Journal of Clinical Oncology. 42(16_suppl). 3116–3116. 1 indexed citations

Geurts, Birgit S., Laurien J. Zeverijn, Jade M. van Berge Henegouwen, et al.. (2024). Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy. The Journal of Pathology. 263(3). 288–299. 4 indexed citations

Verkerk, Karin, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2023). 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP). Annals of Oncology. 34. S797–S798. 3 indexed citations

Geurts, Birgit S., Laurien J. Zeverijn, Gijs F. de Wit, et al.. (2023). Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol. The Oncologist. 29(5). 431–440. 3 indexed citations

10.

Geurts, Birgit S., Laurien J. Zeverijn, Thomas Battaglia, et al.. (2023). Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.. Journal of Clinical Oncology. 41(16_suppl). 2590–2590. 4 indexed citations

11.

Zeverijn, Laurien J., Subotheni Thavaneswaran, Jade M. van Berge Henegouwen, et al.. (2023). Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.. Journal of Clinical Oncology. 41(16_suppl). 3101–3101. 2 indexed citations

12.

Henegouwen, Jade M. van Berge, Louisa R. Hoes, Hanneke van der Wijngaart, et al.. (2022). Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. European Journal of Cancer. 171. 114–123. 16 indexed citations

13.

Koole, Wouter, Anne M.L. Jansen, Margreet G.E.M. Ausems, et al.. (2022). EP313/#490 Validation of mutation analysis of ovarian cancer predisposition genes in tumor tissue. A180.2–A181.

14.

Hoes, Louisa R., Hanneke van der Wijngaart, Laurien J. Zeverijn, et al.. (2021). 1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort. Annals of Oncology. 32. S989–S989.

15.

Hoes, Louisa R., Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, et al.. (2020). 594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients. Annals of Oncology. 31. S498–S498. 2 indexed citations

16.

Jansen, Anne M.L., Carli M.J. Tops, Dina Ruano, et al.. (2019). The complexity of screening PMS2 in DNA isolated from formalin-fixed paraffin-embedded material. European Journal of Human Genetics. 28(3). 333–338. 10 indexed citations

17.

Jansen, Anne M.L., Heleen M. van der Klift, Carli M.J. Tops, et al.. (2018). RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing. European Journal of Human Genetics. 26(8). 1143–1150. 5 indexed citations

18.

Jansen, Anne M.L., Tom van Wezel, Marina Ventayol García, et al.. (2015). Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. European Journal of Human Genetics. 24(7). 1089–1092. 96 indexed citations

19.

Willemsen, Annelieke E.C.A.B., Filip De Vos, Anne M.L. Jansen, et al.. (2014). Diagnostic challenges of respiratory adverse events during everolimus treatment. Targeted Oncology. 9(3). 287–291. 5 indexed citations

20.

Pinheiro, Paulo S., Anne M.L. Jansen, Heidi de Wit, et al.. (2014). The BAR Domain Protein PICK1 Controls Vesicle Number and Size in Adrenal Chromaffin Cells. Journal of Neuroscience. 34(32). 10688–10700. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact